Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,930 DKK | -0.54% | -0.36% | -10.44% |
06-04 | Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating | MT |
06-03 | Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.44% | 18.19B | |
+19.12% | 125B | |
+14.40% | 108B | |
-4.55% | 24.57B | |
+3.23% | 22.82B | |
-41.74% | 16.54B | |
-12.37% | 16.5B | |
+2.66% | 13.39B | |
+27.66% | 11.1B | |
+81.36% | 9.22B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Transcript : Genmab A/S Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-13-2022 08